Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Chris O'Brien Lifehouse, Camperdown

Monash Medical Centre, Clayton

CHU de Caen - Hopital Cote de Nacre, Caen

University of Pennsylvania Abramson Cancer Center, Philadelphia

Marlene & Stewart Greenbaum Comprehensive Cancer Center, Baltimore

University of Maryland Medical Center, Baltimore

CHRU de Brest - Hopital Augustin Morvan, Brest

Institut Bergonie, Bordeaux

H. Lee Moffitt Cancer Center & Research Institute, Tampa

CHU de Nantes - Hôpital Nord Laennec, Saint-Herblain

Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy, Siena

Masonic Cancer Center - University of Minnesota, Minneapolis

CHRU de Lille, Lille

Evangelisches Krankenhaus Hamm, Hamm

Institut Curie - Oncologie Medicale, Paris

University of California, Los Angeles (UCLA) - Medical Center, Los Angeles

Universitatsklinikum Regensburg, Regensburg

University of California, San Francisco (UCSF), San Francisco

Petrov National Medical Research Center of Oncology, Saint Petersburg

Volgograd Regional Clinical Oncology Dispensary, Volgograd

Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Québec

Centre Hospitalier Lyon Sud, Pierre-Bénite

Med Polonia Sp. z o.o., Poznan

Centrum Onkologii Instytut im. Marii Sklodowskiej - Curie, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warsaw

Derriford Hospital ; Derriford Hospital, Plymouth

Beatson, West of Scotland Cancer Centre, Glasgow

Royal Marsden Foundation Trust, Sutton

Guy's and St. Thomas' NHS Trust, London

Churchill Hospital, Oxford